• HPR122 Including Decision Uncertainty About the Clinically Minimal Important Differen Shifting From Risk Aversion to Risk Awareness in Drug Reimbursement Processes

    Dec 1, 2025, 00:00

  • EPH79 Epidemiology and Institutional Treatment Distribution of Patients With Myelofibrosis (MF) in Germany: Insights From a Real-World Evidence Study

    Dec 1, 2025, 00:00

  • PCR52 Content Validation of a Modified PozQoL for Assessing HIV Therapies

    Dec 1, 2025, 00:00

  • RWD122 Medical Resource Utilizations and Economic Burden of Chemotherapy-Induced Anemia in Chinese Population: A Multicenter Retrospective Study

    Dec 1, 2025, 00:00

  • MSR15 Advancing Target Trial Emulation With Synthetic Data: The Target Trial Optimization Framework

    Dec 1, 2025, 00:00

  • EE728 The VIS1ON Horizon Scanning Model: Predicting the Evolution of Direct NHS Expenditure for Type 1 Diabetes in Italy up to 2028

    Dec 1, 2025, 00:00

  • EE44 All-Cause Healthcare Resource Use in Recurrent Respiratory Papillomatosis: A Claims-Based Comparison With Matched Controls

    Dec 1, 2025, 00:00

  • CO95 Efficacy and Safety of Once-Weekly and Once-Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of Clinical Trials

    Dec 1, 2025, 00:00

  • PCR231 The Impact of Inhaler Technique on the Health Outcomes and Cost Among Adults With Asthma and Chronic Obstructive Pulmonary Disease in Saudi Arabia

    Dec 1, 2025, 00:00

  • HSD63 Inequity in Public Healthcare Utilization Among Persons With Disabilities in Bangladesh: A Benefit Incidence Analysis

    Dec 1, 2025, 00:00

  • MSR185 ShinyMMD: An Open-Source Shiny Web Application for a Computer Simulation Model for Type 2 Diabetes and Its Complications

    Dec 1, 2025, 00:00

  • HTA16 A Systematic Literature Review of the Mitigation Strategies to Overcome the Risk for Confounding of Overall Survival in Trials With Crossover/Treatment Switching Evaluated in Health Technology Assessments of Treatments for Select Tumo ...

    Dec 1, 2025, 00:00

  • SA64 Mapping Disease-Specific Patient-Reported Outcome Measures (PROMs) to EQ-5D Utility Scores: A Systematic Review

    Dec 1, 2025, 00:00

  • PCR60 Development of a Discrete Choice Experiment to Explore Preferences for Self-Sampling in a National UK Cervical Screening Program

    Dec 1, 2025, 00:00

  • EE275 Cost-Effectiveness of Smartphone-Based Screening for Obstructive Sleep Apnea: A Markov Model Analysis From the German Statutory Health Insurance Perspective

    Dec 1, 2025, 00:00

  • MSR36 Artificial Intelligence in Systematic Reviews: An Investigation Into the Impact of Eligible Studies Being Excluded by Artificial Intelligence

    Dec 1, 2025, 00:00

  • EE507 Healthcare Resource Utilization in Patients With Hidradenitis Suppurativa Using Adelphi Real-World Data From EU5 and US

    Dec 1, 2025, 00:00

  • EPH68 Effect of Education Given to Nursing Students on Their Palliative Care Knowledge and Attitudes

    Dec 1, 2025, 00:00

  • HTA176 Health Technology Assessments of Oncology Orphan and Advanced Therapies: The Case for Incorporating Real-World Evidence Patient-Reported Outcomes and Indirect Treatment Comparisons Into Joint Clinical Assessment Submissions

    Dec 1, 2025, 00:00

  • EE288 Costs Associated With Kidney Transplant in Portugal

    Dec 1, 2025, 00:00

  • EE560 Introducing the Parameter Outcome Overview Plot: A New Addition to the Sensitivity Analysis Armory for Economic Models

    Dec 1, 2025, 00:00

  • HSD112 Transforming Pediatric Type 1 Diabetes Care in Bulgaria Through Structured Patient Journey Analysis

    Dec 1, 2025, 00:00

  • HPR157 Paying for Advanced Therapy Medicinal Products: Are Spreading Payments Over Time the Solution?

    Dec 1, 2025, 00:00

  • EE81 Budget Impact Analysis of Dimethyl Fumarate for the Treatment of Relapsing/Remitting Multiple Sclerosis in Iraq

    Dec 1, 2025, 00:00

  • PCR134 Impacts of Patient-Centered Collaboration: Application of a Continuous Engagement Plan Across Multiple Phases of the Insights and Patient Experiences With Cardiovascular Disease (IPEC) Initiative

    Dec 1, 2025, 00:00

  • EE363 Economic Burden Of Primary Biliary Cholangitis (PBC) in Spain

    Dec 1, 2025, 00:00

  • EPH192 Prevalence of Obesity and Comorbidities Among People With Obesity in China, Japan, and EU5

    Dec 1, 2025, 00:00

  • RWD48 DARWIN EU® Characterizing Clinically Recognized Hypertrophic Cardiomyopathy in Six European Countries: A Descriptive Analysis Using Real-World Data

    Dec 1, 2025, 00:00

  • EE747 Value-Based Assessment of Trifluridine Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

    Dec 1, 2025, 00:00

  • PCR126 Identifying Patient-Reported Outcome Measures to Capture Patients’ Experiences of Symptoms and Impacts of Acute Myeloid Leukemia (AML)

    Dec 1, 2025, 00:00

  • HPR49 Comparing the Time to Reimbursement of the Orphan Drug Evrysdi in Turkiye vs. Euro-5 Markets

    Dec 1, 2025, 00:00

  • EE579 Micro-Costing Analysis of the Economic Burden of Metabolic Dysfunction-Associated Steatohepatitis and Its Comorbidities in Saudi Arabia

    Dec 1, 2025, 00:00

  • CO12 APDS Treatment in Germany: Decision Criteria, Costs, and Contribution of Leniolisib to Outcomes

    Dec 1, 2025, 00:00

  • HTA200 Individual Therapy or No Therapy at All: Impact of Patient Individual Therapies As ACT in the German AMNOG Process

    Dec 1, 2025, 00:00

  • RWD86 From Clinic to Cohort: The VOICE Vitiligo Registry and Bioresource as a Blueprint for High-Fidelity Specialist Registries

    Dec 1, 2025, 00:00

  • EE99 Budget Impact Analysis of Tenecteplase vs. Alteplase for Adults With Acute Ischemic Stroke (AIS) in Greece

    Dec 1, 2025, 00:00

  • HPR14 Access and Evolving Eviden A European HTA Analysis of Innovative Medicines Under Evidence Generation Agreements

    Dec 1, 2025, 00:00

  • EPH157 Length of Stay (LOS) and Associated Healthcare Resource Use (HCRU) for a First Infusion of Axi-cel or Lisocel in Second Line for Large B-cell Lymphoma in Fran Differences Observed From Comprehensive Hospital Databases

    Dec 1, 2025, 00:00

  • P39 Seeking Patient and Public’s Opinions to Determine Target Differences in Clinical Trials: A Scoping Review of Elicitation Methods

    Dec 1, 2025, 00:00

  • PCR30 Beyond the Conversation: A Narrative Review of Cost-Informed Shared Decision Making and Its Impact on Medication Adherence in Chronic Conditions

    Dec 1, 2025, 00:00

  • CO102 Estimating the Mean Time in Treatment-Free Remission for Patients in Early Line CML

    Dec 1, 2025, 00:00

  • CO144 Improvements in Scalp Outcomes With Roflumilast Foam 0.3% for Psoriasis of the Scalp and Body From the Phase 3 ARRECTOR Trial

    Dec 1, 2025, 00:00

  • EE321 Design and Early Insights From the Pre-HDBOI Study: A Multicountry Real-World Assessment of the Burden in Pre-Motor Manifest Huntington’s Disease

    Dec 1, 2025, 00:00

  • EPH100 Examining The Relationship Between Diabetes Mellitus and Eating Disorders

    Dec 1, 2025, 00:00

  • EE419 Estimating Health Utility Decrements Associated With Chronic Disease Outcomes Using MEPS

    Dec 1, 2025, 00:00

  • HPR102 From Deficit Risk to Surplus Strength: A Revenue-Centered Analysis of Türkiye’s General Health Insurance 2015-2024

    Dec 1, 2025, 00:00

  • MSR173 Projected Rapid-Growing Economic Burden of Chronic Respiratory Multimorbidity in Singapore: Unveiling Diagnostic Gaps and Asian Phenotypes Through Health Administrative Data

    Dec 1, 2025, 00:00

  • RWD20 Assessing the Clinical and Economic Burden of Surgical Bleeding in Switzerland

    Dec 1, 2025, 00:00

  • EE652 Review of CEESP ICERs for Orphan and Nonorphan Treatments in France, 2024-2025

    Dec 1, 2025, 00:00

  • PCR4 A Conceptual Framework for Enhancing the Clinical Utility of a Generic Veterinary Health-Related Quality of Life (HRQoL) Tool Vetmetrica™ Through the Addition of a Disease-Specific Module

    Dec 1, 2025, 00:00

  • HTA367 What Is the Impact of Patient Voice on NICE Recommendations for Drugs Assessed in 2024?

    Dec 1, 2025, 00:00

  • HTA198 Importance of Decisional Context in the Health Technology Assessment (HTA) of Ultra-Orphan Drugs

    Dec 1, 2025, 00:00

  • HPR19 Alternative Pricing Policies for Multi-Indication Products: A Quantitative Analysis

    Dec 1, 2025, 00:00

  • EPH236 The Health Impact of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab Treatment for High-Risk Early Stage Triple-Negative Breast Cancer (eTNBC) in Türkiye

    Dec 1, 2025, 00:00

  • PCR212 Satisfact-Home: Perception of Care Quality and Quality of Life in Patients With Solid Tumors Receiving Immune Checkpoint Inhibitors (ICIs) Therapy From Hospital To Home: A French Multicenter Prospective Observational Study

    Dec 1, 2025, 00:00

  • PCR63 Development of Two Versions of a Patient-Preference Questionnaire for Evaluating Potential HIV Cure-Related and Other HIV Interventions

    Dec 1, 2025, 00:00

  • HTA54 Beyond RCTs: The Role of Patient Perspectives and Nontraditional Evidence in HTA Decisions for Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • MSR153 Natural Language Processing Solution (REALLI) to Evaluate the Limitations of the French National Health Insurance Database (SNDS): Example of HER2+ Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • HTA266 Patient Preference Studies in HTA for Rare Diseases: A Cross-Country Analysis of EU-4, UK, and Canada

    Dec 1, 2025, 00:00

  • PCR35 Can We Quantify the Financial Impact of Patient-Reported Outcomes on the Value of Oncology Products?

    Dec 1, 2025, 00:00

  • PCR180 Patient Preferences for Type 2 Diabetes Mellitus (T2DM) Treatment: A Systematic Review of Discrete Choice Experiments Studies

    Dec 1, 2025, 00:00

  • HTA5 A Cross-Sectional Analysis of Early Access Programs in NICE Health Technology Assessments

    Dec 1, 2025, 00:00

  • P19 Treatment Burden and Quality of Life in Patients With nAMD and DME in Colombia: A Mixed Methods Study

    Dec 1, 2025, 00:00

  • RWD171 Scaling Responsible Healthcare Data Access With AI-Driven Sensitive Patient Variable Detection

    Dec 1, 2025, 00:00

  • RWD60 Development and Implementation of a Dynamic Framework for Assessment and Improvement of Registries’ Data Quality

    Dec 1, 2025, 00:00

  • MSR14 Advancing Multiple System Atrophy Diagnosis: Combining AI and Decision Analysis

    Dec 1, 2025, 00:00

  • EE555 Inpatient Burden of Influenza and Influenza-Like Illness Among Adults Aged 60 and Older in Germany 2019-2024

    Dec 1, 2025, 00:00

  • HPR161 Physicians’ Knowledge, Attitude, and Practice Regarding Medical Liability: A Study in Saudi Arabia

    Dec 1, 2025, 00:00

  • HTA219 Level of ICER of Health Economic Assessment in France in 2024

    Dec 1, 2025, 00:00

  • EE359 Economic Burden of COVID-19-Related Hospitalizations in Finland: A 4-year Longitudinal Analysis

    Dec 1, 2025, 00:00

  • EPH226 Tendencies in the Public-Funded Hungarian One-Day Surgical Care

    Dec 1, 2025, 00:00

  • EE519 Hereditary Transthyretin Amyloidosis (ATTRv) Below the Age of 70 Healthcare Resource Utilization and Mortality

    Dec 1, 2025, 00:00

  • MT5 Artificial Intelligence in Health Economics: Opportunities and Challenges for the Future: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA53 Beyond Productivity: How Professional Identity Shapes Generative AI Adoption Among Medical Writing Professionals

    Dec 1, 2025, 00:00

  • MSR226 Workforce Matters: Defining Labor Input for Better Health Technology Assessment

    Dec 1, 2025, 00:00

  • CO79 Early Change in Proteinuria as a Surrogate Endpoint in Studies of IgA Nephropathy: An Updated Patient-Level Meta-Analysis and Discussion of Appropriate Methodology

    Dec 1, 2025, 00:00

  • EPH92 Evaluating Performance of the Experimental EQ-TIPS (V3) for Assessing Infants and Toddlers With Acute Infections: A Mixed-Methods Approach of Cognitive Debriefing and Psychometric Testing

    Dec 1, 2025, 00:00

  • SA30 Designing Digital Healthcare Professional Surveys: A Methodological Overview

    Dec 1, 2025, 00:00

  • HPR169 Randomized Controlled Trials (RCTs) Are the Gold Standard: Are They Always Used?

    Dec 1, 2025, 00:00

  • HPR64 Drivers and Barriers of Biosimilar Uptake in APAC

    Dec 1, 2025, 00:00

  • EPH94 Evaluation of Participation Data in the Context of Cancer Prevention

    Dec 1, 2025, 00:00

  • CO163 Matching-Adjusted Indirect Comparison of Obecabtagene Autoleucel vs. Blinatumomab Inotuzumab Ozogamicin and Ponatinib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukemia

    Dec 1, 2025, 00:00

  • RWD15 Air Pollution Signals and National Demand for Asthma Medication in Brazil Between 2018-2023: Should It Be Considered a Public-Health Concern?

    Dec 1, 2025, 00:00

  • HSD5 AI-Enabled Extraction of eGFR and BRAF Testing Patterns in Advanced NSCLC: IMPACT-NSCLC, a Multicenter Real-World Study (2019-2024)

    Dec 1, 2025, 00:00

  • EE458 Exploring the Economic Burden Associated With Chronic Obstructive Pulmonary Disease (COPD) Due to Alpha1 Antitrypsin Deficiency (AATD): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EE658 Societal and Economic Impact of Immunotherapy for NSCLC Treatment in Bulgaria

    Dec 1, 2025, 00:00

  • EE558 Integrating Stakeholder Willingness-to-Pay Using the Van Westendorp Price Sensitivity Meter Into Cost-Effectiveness Analysis: A Mixed-Methods Pricing Framework

    Dec 1, 2025, 00:00

  • CO45 Clinical Efficacy and Safety of Targeted Therapies for HER2 Mutant Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HTA350 Use of Data From Phase 3 RCTs in Earlier Lines of Therapy in Support of Noncomparative Evidence From Pivotal Phase 2 Studies

    Dec 1, 2025, 00:00

  • HTA48 Assessment of the Inclusion and Importance of Carer Quality of Life in Global Health Technology Appraisals

    Dec 1, 2025, 00:00

  • HSD56 Healthcare Costs in Older Adults: XGBoost, NNA, and Logit

    Dec 1, 2025, 00:00

  • RWD17 An Algorithm to Identify Immunocompromised Patients in French Claims Data for Rapid Preventive or Therapeutic Interventions

    Dec 1, 2025, 00:00

  • EE19 A Health Economic Evaluation of Daylight: A Digital Treatment for Anxiety in NHS South Yorkshire

    Dec 1, 2025, 00:00

  • PCR243 The SISAQOL-IMI Recommendations on Standardizing the Use of Thresholds for Interpretation of Patient-Reported Outcome Results in Cancer Clinical Trials

    Dec 1, 2025, 00:00

  • MSR29 Application of Network Meta-Analysis in Vaccine Research: An Illustration Using Immunogenicity of Pneumococcal Vaccines in Adults

    Dec 1, 2025, 00:00

  • RWD164 Real-World Treatment Patterns and Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Previously Treated With First-Line (1L) Platinum-Based Chemotherapy (PBC)

    Dec 1, 2025, 00:00

  • EE377 Economic Evaluation of Cefiderocol for the Treatment of Confirmed MBL-Producing Pathogens in Italy

    Dec 1, 2025, 00:00

  • EPH207 Reported Herpes Zoster Incidence Rates in Immunocompromised Adults Aged 18 Years or Older in England by Ethnicity and Socioeconomic Status: A Large Retrospective Cohort Study

    Dec 1, 2025, 00:00

  • PCR49 Comparing Health-Related Quality of Life in Obese Patients With and Without Bariatric Surgery: A Cross-Sectional Study in a Multi-Ethnic Asian Population in Singapore

    Dec 1, 2025, 00:00

  • HSD28 COVID-19's Effects on Mental Health Services: The Effectiveness of Telepsychiatry and Challenges in Substance Use Disorders in the United States

    Dec 1, 2025, 00:00

  • EE79 Budget and Time Impact Analysis of Introducing Subcutaneous Pembrolizumab to Patients From Institution HCP and Patient Perspectives in the United States (US)

    Dec 1, 2025, 00:00

  • CO21 Association Between Invasive Disease-Free Survival/Distant Recurrence-Free Survival and Overall Survival in Patients With Early Stage Triple-Negative Breast Cancer

    Dec 1, 2025, 00:00

  • RWD43 Comprehensive Landscape Assessment of Real-World Databases for HEOR Studies in the Asia-Pacific Region: A Growing Opportunity

    Dec 1, 2025, 00:00

  • EE537 Impact of Mucus Plugs on the Health Economic Burden in Chronic Obstructive Pulmonary Disease (COPD) Patients

    Dec 1, 2025, 00:00

  • MSR11 Accounting for Cure Rates Estimated from Progression-Free Survival (PFS) in Long-Term Overall Survival (OS) Projections: A Case Study from Previously Treated Advanced Cancers

    Dec 1, 2025, 00:00

  • PCR47 Collecting Patient Preference Information (PPI) in In-Trial/Exit Interviews: Current Perspectives and Future Considerations

    Dec 1, 2025, 00:00

  • CO147 Improving Pulmonary Tuberculosis Treatment Outcomes Through Pharmacist-Led Education: Findings From a Malaysian Randomized Control Trial

    Dec 1, 2025, 00:00

  • PCR216 Significant Burden of Chronic Obstructive Pulmonary Disease (COPD) on Health Status and Well-Being Persists Among Patients Experiencing One Severe or Two or More Moderate Exacerbations of COPD (ECOPD) and Their Caregivers (CGs)

    Dec 1, 2025, 00:00

  • CO82 Economic and Clinical Impact of Advanced Therapies in Moderate-to-Severe Rheumatoid Arthritis in Spain: CIARA Study

    Dec 1, 2025, 00:00

  • MSR208 Uncovering Patient Narratives of Opioid Use and Recovery Using Large Language Models for Topic and Emotion Analysis of Social Media Discussions

    Dec 1, 2025, 00:00

  • CO55 Comparative Efficacy and Safety of Delgocitinib, Alitretinoin, and PUVA in Patients With Moderate-to-Severe Chronic Hand Eczema: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • EE705 The Economic Impact of Time-to-Target-Temperature of Different Surface Cooling Technologies for Temperature Management in Critically Ill Patients: A Systematic Review, Analysis, and Model

    Dec 1, 2025, 00:00

  • EE143 Comparison of Nonstatin Lipid-Lowering Therapies (LLTs) by Their Annual Cost per Effectively Treated Very High-Risk Patient in Spain

    Dec 1, 2025, 00:00

  • EE157 Cost and Healthcare Resource Utilization Associated With Chronic Inducible Urticaria: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • PCR76 EQ-5D Utility Trends in NMOSD: Impact of Time and Disability

    Dec 1, 2025, 00:00

  • PCR77 Equivalence of Measurement Properties of the Dermatology Life Quality Index (DLQI) Across 13 European Countries

    Dec 1, 2025, 00:00

  • P4 Simulating Sponsor-HTA Conversations: A Multi-Agent GenAI Framework for Reimbursement Processes

    Dec 1, 2025, 00:00

  • MSR193 Synthetic Data Generation Methods Using Artificial Intelligence (AI): A Simple New AI Tool That Generates Synthetic Data Using Generative Adversarial Network (CTGAN), Copula GANs, and Sequential Decision Tree Methods

    Dec 1, 2025, 00:00

  • EPH253 The Relevance of the Use of TENS Devices in the Therapy of Poststroke Dysphagia

    Dec 1, 2025, 00:00

  • MSR60 Comparison EQ-5D-Y-3L Responses Between Child Self-Reports and Caregiver Proxy Reports

    Dec 1, 2025, 00:00

  • HPR86 Exploring Off-Label Drug Coding Trends in French Hospitals: A Descriptive and Stratified Analysis 2020-2024

    Dec 1, 2025, 00:00

  • EE116 Burden of Disease in Hereditary Transthyretin Amyloidosis With Polyneuropathy in Spain

    Dec 1, 2025, 00:00

  • MSR192 Survival Model Uncertainty in Economic Modeling: Evaluating Bootstrap and Cholesky Decomposition Methods

    Dec 1, 2025, 00:00

  • MSR30 Applying G-methods to Account for Treatment Switching in Postmarketing Effectiveness Evaluation: A Case Study of GLP-1 Receptor Agonists for Diabetic Kidney Disease

    Dec 1, 2025, 00:00

  • EE328 Development of a Partitioned Survival Model Template for Oncology Indications: A Flexible and Customizable Framework

    Dec 1, 2025, 00:00

  • CO189 Primary Lateral Sclerosis (PLS): A Targeted Literature Review of Symptoms, Progression, and Outcomes to Inform Evidence Gaps for Rare Neurological Disorders

    Dec 1, 2025, 00:00

  • EPH40 Characterizing the Use of Janus Kinase Inhibitors (JAKi) in Five European Countries: A Drug Utilization Study

    Dec 1, 2025, 00:00

  • EE678 Systematic Review of Decision-Analytic Models Estimating the Economic Impact of Prescription Opioid Use and Associated Adverse Events

    Dec 1, 2025, 00:00

  • EE16 A Cost-Utility Analysis of Ferric Derisomaltose vs. Ferric Carboxymaltose in Patients with Iron Deficiency Anemia and Inflammatory Bowel Disease in the United Kingdom: Accounting for Difference in Fracture Risk

    Dec 1, 2025, 00:00

  • EE192 Cost-Consequence and Clinical Impact of NGS Testing in Advanced Lung Adenocarcinoma: Real-World Evidence From a Portuguese Public Hospital

    Dec 1, 2025, 00:00

  • EE563 Launch Price Dynamics of Targeted Therapies in NSCLC: Dissecting the Cost and Value Across Biomarker Segments

    Dec 1, 2025, 00:00

  • EE670 Spinal Muscular Atrophy Treatments in Fran What Are the Organizational Economic and Environmental Impacts of Oral and Intrathecal Administrations

    Dec 1, 2025, 00:00

  • Poor Patient Care Outcomes and Nurse Job Outcomes Associated With Unfavorable Intensive Care Unit and Emergency Department Nurse Work Environments: Implications for Critical Care Medicine

    Dec 1, 2025, 00:00

  • HTA117 Dutch Cost Implications of Faricimab in Neovascular Age-Related Macular Degeneration: A Systematic Review of Treatment Interval and Injection Frequency

    Dec 1, 2025, 00:00

  • RWD151 Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Atopic Dermatitis in Poland in Comparison With Efficacy Reported in Clinical Trials

    Dec 1, 2025, 00:00

  • CO155 Inter-Version Comparison of the Boston Carpal Tunnel Questionnaire: A Clinical Validation Study of the Decision Tree-Based Version

    Dec 1, 2025, 00:00

  • P52 Evolution of Risk-Sharing Agreements for Orphan Drugs 2015-2024

    Dec 1, 2025, 00:00

  • MSR143 Matching Adjusted Indirect Comparison of Asciminib vs. Flumatinib as First-Line Treatment for Chronic Myeloid Leukemia in China

    Dec 1, 2025, 00:00

  • HSD89 Population-Level Impact Assessment of the Revised Dyslipidemia Prescription Protocol in Greece Using Simulation Modeling

    Dec 1, 2025, 00:00

  • EE203 Cost-Effectiveness Analysis of Health2Sync Application With Patient Management Program Compared to Traditional Care for Patients With Type 2 Diabetes Mellitus in Taiwan

    Dec 1, 2025, 00:00

  • EE292 Cost-Savings Analysis of Fitusiran Prophylaxis: Reducing Breakthrough Bleeding Treatment Expenditure in the Kingdom of Saudi Arabia

    Dec 1, 2025, 00:00

  • HTA227 Mapping Writer-AI Conversations for HTA: Preliminary Analysis of 7009 Messages

    Dec 1, 2025, 00:00

  • P56 An Early Start: Preliminary Indirect Treatment Comparison Assessments Informing Evidence-Generation Planning for Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • SA59 Laboratory Testing Patterns in Patients With Breast Cancer Treated With CDK4/6 Inhibitors: A Multi-Country Electronic Health Record Study From the UK, Germany, and Japan

    Dec 1, 2025, 00:00

  • HTA343 US Payer Assessment of the Utility and Impact of Value Dossiers on Decision Making

    Dec 1, 2025, 00:00

  • HPR126 Integrating Guidance Through a Whole Life-Cycle Approach: Wouldn’t It Be NICE?

    Dec 1, 2025, 00:00

  • MSR115 Generation of Synthetic Patient Data to Overcome Machine Learning Limitations in Healthcare Research: A Systematic Review of Methods, Performance, and Use Cases

    Dec 1, 2025, 00:00

  • EE216 Cost-Effectiveness Analysis of Pharmacogenetic Testing to Guide Treatment for Children With Asthma

    Dec 1, 2025, 00:00

  • HTA75 Clinical Benefit vs. Reimbursement Decisions: Examining Misalignments Between ESMO-MCBS and HTA Outcomes in Oncology

    Dec 1, 2025, 00:00

  • PCR236 The Mediating Role of Insomnia in the Relationship Between Disease Severity and Mental Health Quality of Life and Productivity in Atopic Dermatitis

    Dec 1, 2025, 00:00

  • EE639 Real-World Healthcare Resource Utilization in Patients With Metastatic Colorectal Cancer Treated With Trifluridine/Tipiracil Plus Bevacizumab or With Regorafenib

    Dec 1, 2025, 00:00

  • RWD28 Characteristics of Patients Treated With Biologic Agents for Moderate-to-Severe Atopic Dermatitis in Poland

    Dec 1, 2025, 00:00

  • PCR228 The Economic Case for Gender Equity: How Closing the Women’s Health Gap Benefits Healthcare Systems and Economies

    Dec 1, 2025, 00:00

  • PCR217 Social Determinants of Health Affecting Response to Opioid Addiction Treatment

    Dec 1, 2025, 00:00

  • HPR94 Feasibility of Indication-Specific Pricing for Life Cycle Management of an Innovative Rare Disease Product

    Dec 1, 2025, 00:00

  • Medicare Drug Price Negotiation Under the Inflation Reduction Act: Ensuring the Continuity of Critical Real-World Pharmaceutical Studies

    Dec 1, 2025, 00:00

  • PCR213 Sex Differences in Patients With Chronic Hand Eczema (CHE): Disease Manifestations and Quality of Life (QoL) Results From a Cross-Sectional Multinational Study

    Dec 1, 2025, 00:00

  • EE492 Health Economic Evaluation Model for Prostate Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • PCR248 Treatment Patterns and Healthcare Resource Utilization Among Patients With Immune Thrombocytopenia: A Real-World Survey

    Dec 1, 2025, 00:00

  • P42 A Systematic Review of Economic Modeling Challenges and Proposed Solutions for Rare Disease Technologies: An HTAi RDIG Initiative

    Dec 1, 2025, 00:00

  • MSR116 Give Us the Tools and We Will Finish the Job: How Accurate Is AI for Study Selection in Systematic Reviews?

    Dec 1, 2025, 00:00

  • EE624 Quantification of Life-Cycle Value Using Early Modeling to Support RD and Strategy Decisions: A Case Study of a Polymeric Heart Valve

    Dec 1, 2025, 00:00

  • HTA31 Analysis of HTA Decisions in Five European Countries for High Medical Need Products Approved by EMA

    Dec 1, 2025, 00:00

  • PCR55 Delayed Access to Diabetes Technology in Children With Migration Background: A Cross-Sectional Study on Treatment Equity in Austria

    Dec 1, 2025, 00:00

  • CO92 Efficacy and Safety of Inhaled Levofloxacin vs. Other Inhaled Antibiotics in the Treatment of Adults With Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection: An Updated Network Meta-Analysis

    Dec 1, 2025, 00:00

  • PCR156 Measuring the Disease Burden and Quality of Life From the Schizophrenia Caregivers’ Perspective

    Dec 1, 2025, 00:00

  • HTA213 Italian Perspective on Rare Disease New Treatments and HTA: Insights From Iptacopan Multidimensional Evaluation in PNH

    Dec 1, 2025, 00:00

  • EE546 Improved Outcomes and Cost Savings With the New-Generation Balloon-Expandable Covered Stent in Aortoiliac Occlusive Disease: Preliminary Results Overview From an Italian Perspective

    Dec 1, 2025, 00:00

  • MSR7 A New Regulatory-Grade Chronic Disease Cohort Simulator: Leveraging the Large, Deep, and Long Constances Cohort Linked and Matched to the SNDS in France

    Dec 1, 2025, 00:00

  • EPH3 A Critical Review of the Screening Criteria Ratings and Recommendations by the UK National Screening Committee (NSC) for 30 Adult Conditions

    Dec 1, 2025, 00:00

  • EPH24 Associations Between Waiting Time and Treatment Completion Among Treatment-Naive Pregnant Cannabis Users Admitted to Treatment Facilities in the United States

    Dec 1, 2025, 00:00

  • RWD27 Challenges and Opportunities in Using Real-World Data for Healthcare in the Middle East and North Africa Region: A Systematic Scoping Review

    Dec 1, 2025, 00:00

  • EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status

    Dec 1, 2025, 00:00

  • MSR96 Evaluating the Reliability of Value of Information Methods: A Simulation-Based Comparison

    Dec 1, 2025, 00:00

  • EE733 Transfusion-Related Cost and Time Burden in JAKi-Naïve and JAKi-Experienced Patients With Myelofibrosis Treated With Momelotinib and Ruxolitinib From the SIMPLIFY 1 and 2 Studies: A Brazilian Supplementary Health Perspective

    Dec 1, 2025, 00:00

  • CO53 Comparative Effectiveness of Alectinib vs. Crizotinib as First-Line Therapy in ALK-Positive Non-Small Cell Lung Cancer: A Real-World Quasi-Experimental Study

    Dec 1, 2025, 00:00

  • MSR20 AI Powered SQL for Real-World Data: From Questions to Insights

    Dec 1, 2025, 00:00

  • HTA360 What Counts? Exploring Stakeholder Perspectives on the Value of Guiding Criteria for Prioritizing Public Funding of Health Technologies

    Dec 1, 2025, 00:00

  • EE340 Do We Need to Measure Social Impact of Innovative Drugs?

    Dec 1, 2025, 00:00

  • RWD96 Health-Related Quality of Life in Adults With Dry Eye Disease in Fran Insights From a Multicenter Observational Study

    Dec 1, 2025, 00:00

  • PT16 Patients’ Advocacy Groups in Italy: An Updated Perspective on Activities and Future Directions

    Dec 1, 2025, 00:00

  • MSR53 Can Generative Artificial Intelligence (GenAI) Be Leveraged to Automate Scoping Searches of Systematic Literature Reviews (SLRs)?

    Dec 1, 2025, 00:00

  • EE211 Cost-Effectiveness Analysis of Lebrikizumab vs. Alternative Biologics in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis in the UK

    Dec 1, 2025, 00:00

  • HSD31 Definitive Staging and Perioperative Treatment for Resectable Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC): A UK Perspective

    Dec 1, 2025, 00:00

  • PCR135 Improving Patient Involvement in Cancer Clinical Trials: Development of Plain Language Checklists Within the SISAQOL-IMI Initiative

    Dec 1, 2025, 00:00

  • EE53 Early Outpatient Follow-up and Reduced Health Care Resource Utilization in Acute Heart Failure in Germany: A Descriptive Analysis

    Dec 1, 2025, 00:00

  • HTA289 Review of Surrogate Endpoints’ Acceptance Trends in German HTA and Implications for EU Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • EE142 Comparing the Economic Burden in Patients With vs. Without Ehlers-Danlos Syndrome (EDS) Using a Large US Electronic Health Records Database

    Dec 1, 2025, 00:00

  • HTA240 National Implementation of the EU HTA Regulation: Progress and Strategic Developments Across Member States

    Dec 1, 2025, 00:00

  • EPH164 Molecular Testing Strategies and Their Impact on Treatment Decision in HR+/HER2- Metastatic Breast Cancer: A Real-World Analysis From German Centers

    Dec 1, 2025, 00:00

  • EE129 Clinical and Economic Burden Imposed by Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Belgium

    Dec 1, 2025, 00:00

  • HTA156 From Pilot to Platform: Expanding Generative AI Coauthoring Across Global Value Dossier (GVD) Sections With Proven Quality and Validation

    Dec 1, 2025, 00:00

  • EPH185 Predictors of Effectiveness of Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs in the Treatment of Rheumatoid Arthritis

    Dec 1, 2025, 00:00

  • MSR90 Evaluating an Automated AI-Driven Pipeline for Literature Surveillance and Synthesis: A Proof-of-Concept for Health Economics and Outcomes Research (HEOR) Communications

    Dec 1, 2025, 00:00

  • MSR205 Transportability of Overall Survival Estimates From the United States to Germany in eGFR+ Advanced NSCLC Patients Post-Tyrosine Kinase Inhibitor (TKI) Treatment

    Dec 1, 2025, 00:00

  • HTA15 A Review of Utility Data Used in Health Technology Assessments From the Perspective of a Health Technology Assessment Body

    Dec 1, 2025, 00:00

  • CO108 Evaluating the Impact of Censoring on Progression-Free Survival Comparisons of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

    Dec 1, 2025, 00:00

  • HSD119 Understanding Trends and Opinions on More Environmentally Friendly Healthcare: A Clinician Survey

    Dec 1, 2025, 00:00

  • HTA284 Reimbursement Challenges for ATMPs in EU5: Learnings From Product Withdrawals and Implications for Future Development of Innovative Therapies

    Dec 1, 2025, 00:00

  • EE20 A Method to Estimate Causally Related Cost Savings of a Preventive Intervention: An Analysis Using the Wellness-Star∗ Database

    Dec 1, 2025, 00:00

  • EPH53 Cost-Effectiveness Analysis of the 13-Valent Pneumococcal Conjugate Vaccine Compared With Higher-Valent Alternatives in the Pediatric Population of Paraguay

    Dec 1, 2025, 00:00

  • PCR186 Perspectives of Patients and Healthcare Providers on a Shared Decision-Making Dashboard in Rheumatoid Arthritis Care

    Dec 1, 2025, 00:00

  • EE430 Evaluating Cost Benefits of Subcutaneous vs. Intravenous Trastuzumab/Pertuzumab in HER2-Positive Early Breast Cancer Patients: From Qatari Healthcare Perspective

    Dec 1, 2025, 00:00

  • PCR124 Identification of Clusters of Patients With Similar Baseline Characteristics in the FOCAL-MS2 Study Evaluating Patient’s Autonomy

    Dec 1, 2025, 00:00

  • SA53 Impact of the Severity of Disease-Related Malnutrition on Healthcare Resource Utilization in Pediatric Patients 1 Year and Older

    Dec 1, 2025, 00:00

  • CO74 Dinutuximab Beta vs. Historical Controls in the Maintenance Therapy of Relapsed Neuroblastoma: Unadjusted and Adjusted Indirect Comparison

    Dec 1, 2025, 00:00

  • EE318 Decision-Analytic Modeling on Imaging Modalities in Breast Cancer Staging: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE218 Cost-Effectiveness Analysis of RefluxStop for Treatment of Chronic Gastro-esophageal Reflux Disease: A US Medicare Perspective

    Dec 1, 2025, 00:00

  • PCR86 Evaluation of the Effectiveness of a Naturalness Probe for Assessing Human- and Nonhuman-Generated COA Translations in Linguistic Validation Cognitive Debriefing Interviews

    Dec 1, 2025, 00:00

  • PCR267 What Affects Quality of Life Most in Oral Cancer Therapy? A Pilot Study of Adherence and Side Effects

    Dec 1, 2025, 00:00

  • EE168 Cost-Effectiveness of Belatacept as Conversion Therapy in the Management of Patients Living With a Renal Graft in France

    Dec 1, 2025, 00:00

  • PCR38 Care Partner Burden and Experiences With Schizophrenia: A National Canadian Survey

    Dec 1, 2025, 00:00

  • HPR81 Evolution of National Price Negotiations for Pharmacy/Retail Medicines (Triparty Negotiations) in Sweden and Implications for Access

    Dec 1, 2025, 00:00

  • HTA57 Bridging National and EU HTA Regulation: Policy Responses to the JCA Rollout

    Dec 1, 2025, 00:00

  • HTA255 NICE Reduces Waiting Times for Technology Adoption: Early Value Assessment As a Pragmatic Approach to Adopting Promising Innovation in the NHS

    Dec 1, 2025, 00:00

  • HSD2 A Comprehensive Approach Including Mailed FITs and Nurse Navigation for Colorectal Cancer Screening

    Dec 1, 2025, 00:00

  • RWD64 Director Primary Data Collection

    Dec 1, 2025, 00:00

  • HPR67 Effect of the Inflation Reduction Act on Drug Innovation

    Dec 1, 2025, 00:00

  • EE10 A Cost-Effectiveness Analysis of First-Line Therapies for Microsatellite-Instability-High (MSI-H) or Mismatch-Repair-Deficient (dMMR) Unresectable or Metastatic Colorectal Cancer (mCRC) in France

    Dec 1, 2025, 00:00

  • HPR230 Unlocking Access: Overcoming Barriers and Harnessing Enablers for Innovative Payment Models for Pharmaceutical Innovation in Europe

    Dec 1, 2025, 00:00

  • HTA113 Disparities in Market Access of ATMPs: A Comparative Analysis of HTA Outcomes Across Europe

    Dec 1, 2025, 00:00

  • EE279 Cost-Effectiveness of T-DM1 vs. Trastuzumab for Adjuvant Treatment in HER2 Early Breast Cancer (eBC) With Residual Disease in Colombia

    Dec 1, 2025, 00:00

  • PCR226 The EB Insights Study: The Impact of Epidermolysis Bullosa on Carer Health-Related Quality of Life

    Dec 1, 2025, 00:00

  • SA29 Design, Implementation, Data Analysis on the Time-Motions Studies: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA84 Comparing ROBINS-I V2 and Downs Black for nRCTs in the Context of HTA

    Dec 1, 2025, 00:00

  • SA42 Feasibility Assessment of a Real-World Comparator Cohort Using Multiple Qualifying Index Lines of Therapy (LOTs) in Third-Line or Later (3L+) Diffuse Large B-cell Lymphoma (DLBCL)

    Dec 1, 2025, 00:00

  • MT17 From Anxiety to Hope: Understanding the Adoption of AI Counseling Tools for Anxiety Management

    Dec 1, 2025, 00:00

  • HTA138 Evidence Strategy Starts Early: Integrating HTA Needs Through PICO Simulation in Metastatic Castration-Resistant Prostate Cancer

    Dec 1, 2025, 00:00

  • RWD90 Granulocyte-Colony Stimulating Factor (G-CSF) Reference and Biosimilar Products Using Real-World Data to Assess Data Variability Across Different Sources to Evaluate its Potential Utility in Regulatory Assessment: A Study by the Biolo ...

    Dec 1, 2025, 00:00

  • MSR49 Bridging the Survival Extrapolation Gap in Health Economic Models: A Case Study on Spline-Based Survival Analysis Using ML-NMR to Address Complex Hazard Function

    Dec 1, 2025, 00:00

  • EE62 Assessing the Health-Related Quality of Life and Economic Burden of Dry Eye Disease in Thailand: A Multi-Center Study on Patient-Reported Outcomes

    Dec 1, 2025, 00:00

  • MT37 Robotic Surgery: A Budget Analysis in the Italian Healthcare Setting

    Dec 1, 2025, 00:00

  • SA92 Testing Automated-Prompt Engineering Strategies for Systematic Literature Review Screening

    Dec 1, 2025, 00:00

  • EPH167 Multi-Level Factors Influencing Active Surveillance Initiation Among Elderly Medicare Beneficiaries Newly Diagnosed With Low-Risk and Favorable Intermediate-Risk Prostate Cancer: An Active Comparator New User Retrospective Cohort Stu ...

    Dec 1, 2025, 00:00

  • EE517 Healthcare Resource Utilization for Patients With Transthyretin Amyloid Cardiomyopathy: A Real-World Study in Europe, Canada, and Japan

    Dec 1, 2025, 00:00

  • EE366 Economic Burden of Systemic Lupus Erythematosus (SLE) Among Women in the USA: A Systematic Review

    Dec 1, 2025, 00:00

  • SA6 Addressing Bias in Indirect Treatment Comparisons: A Framework for Identifying TEMs and PVs

    Dec 1, 2025, 00:00

  • PT31 Systemic Solutions Influencing Physicians' Prescription Behavior Leading to Savings in the Reimbursement Budget in European Countries: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE701 The Economic Burden of Moderate and Severe Anxiety and Depression Symptoms in Saudi Arabia

    Dec 1, 2025, 00:00

  • EPH106 Exploring the Broader Value of Adult Respiratory Vaccination Programs in Gree A Public Health Perspective

    Dec 1, 2025, 00:00

  • SA79 Real-World Treatment Patterns Among Patients Newly Diagnosed With Chronic Inflammatory Demyelinating Polyneuropathy in the United States

    Dec 1, 2025, 00:00

  • SA41 Factors Associated With the Publication of Real-World Evidence Studies in Lung Cancer by Journal Impact Factor

    Dec 1, 2025, 00:00

  • MSR39 Assessing Bias in LLM-Extracted Real-World Data: A Health Equity Analysis of Access to Care and Outcomes in Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • MSR73 Development of Cardiovascular Risk Equations: Integrating Clinical Expertise With Data From the SELECT Trial

    Dec 1, 2025, 00:00

  • HTA179 How Impactful Is Time to Next Treatment on Health Technology Assessment Outcomes in Indolent Cancers?

    Dec 1, 2025, 00:00

  • EE565 Lifetime Secondary Healthcare Resource Utilization in Phenylketonuria From Birth to Adulthood in Sweden

    Dec 1, 2025, 00:00

  • HTA112 Digital Health Technologies Assessment Based on Patient-Reported Outcome Measures (PROMs): Virtual Reality (VR) in the Treatment of Specific Phobias

    Dec 1, 2025, 00:00

  • SA52 Impact of Different Thresholds of Increasing or Decreasing Body Mass Index on Noncommunicable Diseases Through a Discrete Event Simulation Model

    Dec 1, 2025, 00:00

  • MSR64 Country-Related Differential Item Functioning in the EQ-5D-5L: Insights From the EuroQol Data Assessment of Population Health Needs and Instrument Evaluation (EQ-DAPHNIE)

    Dec 1, 2025, 00:00

  • EE601 Optimizing HER2+ Breast Cancer Treatment Pathways in Italian Oncological Centers

    Dec 1, 2025, 00:00

  • CO252 Tocilizumab vs. Sarilumab Among Adults Hospitalized Due to COVID-19: A Federated Comparative Effectiveness Study Across England and Scotland Under the Target Trial Emulation Framework

    Dec 1, 2025, 00:00

  • EPH261 Trends in Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Prescribing in England: A Data Analysis Using NHS Prescription Episodes Statistics (PES)

    Dec 1, 2025, 00:00

  • HTA306 Surrogate Endpoints in German Health Technology Assessment: Post Hoc Analyses of the Phase III PROTECT Study Highlight the Efficacy of Sparsentan in Slowing Down the Loss of Kidney Function in IgAN Patients

    Dec 1, 2025, 00:00

  • CO157 Investigating the Patient-Relevance of Achieving Blood Phe Thresholds in PKU: Results From an Analysis of the OPAL Study

    Dec 1, 2025, 00:00

  • HPR171 Reframing Pharmaceutical Pricing: Implications of the 2025 SVR Report for Germany’s Pricing Logic and International Spillovers

    Dec 1, 2025, 00:00

  • EE570 Malnutrition-Related Healthcare Costs in Hospitalized IBD Patients: A Nationwide Real-World Data Analysis in Italy

    Dec 1, 2025, 00:00

  • EE688 The Clinical Humanistic and Economic Burden of the Current Management of Patients With Recurrent Malignant Ascites in the UK and Europe

    Dec 1, 2025, 00:00

  • SA31 Determining the Minimal Important Difference of EQ-5D-5L Utility Values in CIDP Patients Using Data From a Large Clinical Trial

    Dec 1, 2025, 00:00

  • SA50 How Much Time Does Artificial Intelligence Really Save in Evidence Synthesis? A Systematic Literature Review

    Dec 1, 2025, 00:00

  • P64 Patient Engagement in Economic Evaluations of Cancer Care: Mapping the Landscape and Advancing Practice

    Dec 1, 2025, 00:00

  • EPH154 Knowledge and Awareness of Primary Care Physicians (PCPs) Towards Respiratory Syncytial Virus (RSV) in Australia, Hong Kong, Japan, New Zealand, South Korea, Singapore, and Taiwan

    Dec 1, 2025, 00:00

  • HTA288 Retrospective Analysis of Hungarian HTA Submissions Under the Former National Health Economics Guideline

    Dec 1, 2025, 00:00

  • CO170 Network Meta-Analysis for an Efficacy Assessment of Avelumab Axitinib in the First-Line Treatment of International Metastatic RCC Database Consortium (IMDC) Favorable Risk Patients With Advanced Renal Cell Carcinoma (ARCC)

    Dec 1, 2025, 00:00

  • MT26 HTA Requirements for Medical Technologies in Germany

    Dec 1, 2025, 00:00

  • HTA23 Addressing Payer Concerns: Opportunities for HEOR in Orphan Drug Development

    Dec 1, 2025, 00:00

  • HPR16 Accessibility and Time to Reimbursement of Treatments With Substantial Benefit: A Comparative Analysis Focused on Inequalities Between Different European Countries and Different Tumor Types

    Dec 1, 2025, 00:00

  • PT25 Systems-Level Modeling Approaches for Complex Health Technologies: A Systematic Review

    Dec 1, 2025, 00:00

  • SA77 Premium Relief Through Prevention: Actuarial Valuation of Herpes Zoster Vaccination

    Dec 1, 2025, 00:00

  • MSR33 Are Economic Models in R That Shiny? Making Cost-Effectiveness Models Shinier by Integrating Artificial Intelligence Applications

    Dec 1, 2025, 00:00

  • EE714 The Impact of Inflation: A Cost Analysis in the Spanish Pharmaceutical Sector From 2014 to 2023

    Dec 1, 2025, 00:00

  • EPH27 Beyond the Guidelines: Exploring the Characteristics and Comorbidity Profiles of Adults With Pneumococcal Disease in England Not Covered by Current Pneumococcal Vaccination Criteria

    Dec 1, 2025, 00:00

  • CO129 Healthcare Resource Utilization and Disease Progression in Patients With Primary Hyperoxaluria: A Retrospective Cohort Study

    Dec 1, 2025, 00:00

  • SA78 Quality of Systematic Reviews With Network Meta-Analyses on JAK Inhibitors in the Treatment of Rheumatoid Arthritis: Application of the AMSTAR 2 Scale

    Dec 1, 2025, 00:00

  • EPH1 A Comparison of the Potential Public Health Impact of PCV15 and PCV20 in French Infants

    Dec 1, 2025, 00:00

  • HTA152 From GVD to HTA: Preparing for Success in the EU JCA Era With GenAI-Enhanced Efficiency

    Dec 1, 2025, 00:00

  • EE87 Budget Impact Analysis of Hyaluronic Acid Viscosupplementation for Knee Osteoarthritis in Colombia

    Dec 1, 2025, 00:00

  • HTA365 What Is Driving the Increase in Terminated NICE Appraisals?

    Dec 1, 2025, 00:00

  • PCR120 Health-Related Quality of Life of Caregivers of Children and Adolescents With Disease in Korea

    Dec 1, 2025, 00:00

  • EE514 Healthcare Resource Utilization and Economic Burden Among Adults With Alopecia Areata in the United Arab Emirates

    Dec 1, 2025, 00:00

  • MSR157 Optimized Piecewise Exponential Modeling Using Dynamic Programming: An Illustration From Treatment-Naïve Advanced Melanoma

    Dec 1, 2025, 00:00

  • PCR10 A Review of Information Uncertainty in Oncology Treatment Preferences

    Dec 1, 2025, 00:00

  • HSD108 The Micro-Meso-Macro (3M) Impact Framework: Capturing Health System Value Across Interacting Levels

    Dec 1, 2025, 00:00

  • RWD80 Evolution of Utilization and Costs of Long-Acting Injectable Antipsychotics (LAIs) in Outpatient Care at Lisbon Psychiatric Hospital (March-May 2022 vs. 2025)

    Dec 1, 2025, 00:00

  • PCR117 Health-Related Quality of Life in Patients Living With Osteosarcoma in Europe: A Systematic Review

    Dec 1, 2025, 00:00

  • SA32 Developing Best Practice for Using Automation Tools in Literature Reviews

    Dec 1, 2025, 00:00

  • EE387 Economic Evaluation of Tarlatamab as Second-Line Therapy for Metastatic Small-Cell Lung Cancer: A United States Perspective

    Dec 1, 2025, 00:00

  • HTA80 Comparator Misalignment As a Contributor to Negative Reimbursement Decisions for Pharmaceuticals in Sweden

    Dec 1, 2025, 00:00

  • EE660 Societal and Economic Impact of NOAC Therapy for Deep Vein Thrombosis and Pulmonary Embolism in Bulgaria

    Dec 1, 2025, 00:00

  • EE360 Economic Burden of Gaucher Disease: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • SA27 Data Reliability in Retrospective Chart Review Studies: Results and Considerations From a Novel Data Review Methodology

    Dec 1, 2025, 00:00

  • SA39 Evaluating the Public Health Impact of Adolescent Meningococcal B (MenB) Vaccination in Fran A Modeling Approach

    Dec 1, 2025, 00:00

  • HTA348 US PIE and AMCP Dossiers: Payer Preferences Best Practice and a Comparison With Global Evidence Dossiers

    Dec 1, 2025, 00:00

  • RWD129 Occupational Disease Claims and Payments in Indonesia: Insights From Administrative Data 2018-2022

    Dec 1, 2025, 00:00

  • HTA316 The Greek Drug Price Negotiation Committee and Its Contribution in Optimizing the Management of EOPYY's Pharmaceutical Budget

    Dec 1, 2025, 00:00

  • MSR66 Dealing With Missing Data in Health Economic Studies of Small to Moderate Size: How to Minimize Bias

    Dec 1, 2025, 00:00

  • PCR250 Treatment Preferences in Adults With Chronic Spontaneous Urticaria Symptomatic on H1-Antihistamines in China: Insights From CHOICE-CSU 2 Study

    Dec 1, 2025, 00:00

  • EE475 Five-Year Clinical and Economic Impact of 20 Weight Loss in Adults With Obesity in Saudi Arabia: A Public Healthcare Perspective

    Dec 1, 2025, 00:00

  • EE214 Cost-Effectiveness Analysis of Oteseconazole vs. Fluconazole for Patients With Severe Vulvovaginal Candidiasis in China

    Dec 1, 2025, 00:00

  • EE536 Impact of Maternal Vaccination Strategy on RSV-Related Hospital Burden Among Infants Aged Less Than One Year in Fran A Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • EE698 The Economic Burden of Acromegaly Disease in the Kingdom of Saudi Arabia

    Dec 1, 2025, 00:00

  • HPR185 Small Molecules vs. Biologics Patterns of Indication Expansion and the Potential Impact of Medicare Price Negotiation

    Dec 1, 2025, 00:00

  • PCR240 The Relevance of Core Outcome Sets to Improving Healthcare Decision Making

    Dec 1, 2025, 00:00

  • EPH109 Exploring the Impact of Socioeconomic Factors on COVID-19 Vaccine Hesitancy in India: What Can We Learn From the COVID-19 Pandemic? A Scoping Review

    Dec 1, 2025, 00:00

  • EE629 Quantifying the Impact of Inconsistencies in Economic Modeling Assumptions: A Case Study in Metastatic Colorectal Cancer

    Dec 1, 2025, 00:00

  • PT18 Evaluating AI Chatbot Empathy and Probing Skills in Automated Patient In-Trial Interviews: A Proof of Principle Experiment

    Dec 1, 2025, 00:00

  • MSR68 Demonstrating the Importance of Modeling Rapid Cancer Progression in Screening Evaluations

    Dec 1, 2025, 00:00

  • HPR91 Factors Associated With Positive Cost-Effectiveness Judgments in HIRA Drug Reimbursement Decisions: An 8-year Retrospective Review

    Dec 1, 2025, 00:00

  • RWD110 Integrating Prospective and Retrospective Real-World Data to Construct External Comparator Arms: Novel Methods and Design Considerations

    Dec 1, 2025, 00:00

  • MSR159 Optimizing Patient Retention in Non–Site-Based Longitudinal Studies: Tailored Follow-up Strategies for Rare Disease Cohorts

    Dec 1, 2025, 00:00

  • EE445 Evaluating the Impact of Subsequent Anticancer Therapy Use on Life-Year and QALY Estimates in Late-Line Metastatic Colorectal Cancer: A Health Economic Analysis of FRESCO-2

    Dec 1, 2025, 00:00

  • EE356 Economic Burden in Metastatic Triple-Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • HTA342 Trends and Tensions in NICE Severity Modifiers: Analyzing the Acceptance and Critique of Manufacturer Severity Modifier Proposals in Recent Appraisals

    Dec 1, 2025, 00:00

  • CO192 Projected Public Health Benefits of Nirsevimab for RSV Prevention in Infants in Greece

    Dec 1, 2025, 00:00

  • HPR56 Disparities in Access to Gene Therapy in the European Union: Ethical and Regulatory Challenges

    Dec 1, 2025, 00:00

  • RWD33 Clinical and Economic Characteristics of eGFR-Mutated NSCLC Patients Treated With TKIs in South Korea: A Retrospective Cross-Sectional Analysis

    Dec 1, 2025, 00:00

  • MSR151 Modeling the Future Clinical and Environmental Burden of Chronic Kidney Disease in Ghana and Uganda Between 2025 and 2030

    Dec 1, 2025, 00:00

  • PCR151 Mapping the Evidence on Interrelationships Between Cancer Stage Financial Toxicity (FT) and Health-Related Quality of Life (HRQoL)

    Dec 1, 2025, 00:00

  • EE668 Spain Leveling Up: A Comparison of Spain’s New National Health Economic Evaluation Guideline With Those of England, France, Germany, Italy, Portugal, Sweden, Ireland, Canada, Australia, and Japan

    Dec 1, 2025, 00:00

  • EE72 BFM 2009 (Berlin, Frankfurt, Munich) Protocol Cost Analysis for Childhood Acute Lymphoblastic Leukemia (ALL): Preliminary Real-World Data From Brazil/LATAM/LMIC

    Dec 1, 2025, 00:00

  • CO253 Transfusion Healthcare Resource Utilization and Associated Impact of Quality of Life Among Patients With Myelofibrosis and Anemia: A Multinational Real-World Survey

    Dec 1, 2025, 00:00

  • MSR119 How Can the Threshold Method Guide the Choice of Treatments? Illustration in French Patients With Hemophilia A or B

    Dec 1, 2025, 00:00

  • EE333 Direct Medical Costs of Home-Based Respiratory Support and Oxygen Therapy for Patients With Chronic Respiratory Failure

    Dec 1, 2025, 00:00

  • RWD189 Use of Big Data to Assess Dyslipidemia Management in Gree Real-World Insights From the National Healthcare Payer

    Dec 1, 2025, 00:00

  • EPH5 A Real-World Study on Hospital and Economic Burden of Dengue Fever in French Overseas Territories

    Dec 1, 2025, 00:00

  • PCR251 Treatment Preferences in Adults With Chronic Spontaneous Urticaria Symptomatic on H1-Antihistamines in the Netherlands: Insights From CHOICE-CSU 2 Study

    Dec 1, 2025, 00:00

  • PCR112 Health-Related Quality of Life (HRQoL) and Its Associated Factors among Chinese Gout Patients: Baseline Findings From a Survey Study

    Dec 1, 2025, 00:00

  • RWD67 Disproportionality Analysis Of Vedolizumab to Identify a Putative Signal Using Real-World Postmarketing Surveillance Data Reported in the FAERS Database

    Dec 1, 2025, 00:00

  • PCR198 Psychometric Validation Of The North Star Assessment For Limb-Girdle Type Muscular Dystrophies (NSAD) In Limb-Girdle Muscular Dystrophy Sarcoglycanopathies (LGMD 2C/2D/2E) Using Baseline JOURNEY Data

    Dec 1, 2025, 00:00

  • MSR19 AI Models for Predicting Clinical Trial Success: Capabilities and Risks of Pattern-Driven Approaches

    Dec 1, 2025, 00:00

  • MT36 Quantifying the Impact of Data Digital and AI on Health Systems

    Dec 1, 2025, 00:00

  • HTA243 Navigating HTA and Innovation: Oncologists’ Perspectives on Access to Cancer Therapies in Bulgaria

    Dec 1, 2025, 00:00

  • RWD163 Real-World Study of Breast Cancer Epidemiology and Treatment Patterns: A Pilot Study to Assess EHR-Derived Data in the United Kingdom

    Dec 1, 2025, 00:00

  • EE500 Healthcare Costs in People With Type 2 Diabetes Remaining on or Escalating From Basal-Supported Oral Therapy: A 5-Year German Statutory Health Insurance Claims Data Analysis

    Dec 1, 2025, 00:00

  • EE474 First-Trimester Screening for Preterm Pre-Eclampsia in the United Kingdom: A Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • HPR234 Utilization of Best-Value Medicines for Teriparatide in the Irish Healthcare Setting

    Dec 1, 2025, 00:00

  • EE261 Cost-Effectiveness of Mixed-Approach Maternal RSVpreF/Infant Nirsevimab Immunization vs. Nirsevimab Alone for Prevention of Respiratory Syncytial Virus in Spain

    Dec 1, 2025, 00:00

  • HTA132 Evaluating High-Cost Gene Therapies for Noncancer Conditions: Insights From NICE's Standard Appraisal Process

    Dec 1, 2025, 00:00

  • EE444 Evaluating the Impact of Different Payment Models on the Cost-Effectiveness and Budget Impact of Cell and Gene Therapies: Eladocagene Exuparvovec As a Case Study

    Dec 1, 2025, 00:00

  • CO228 Systematic Literature Review of Artificial Intelligence-Based Models Predicting COPD Exacerbations

    Dec 1, 2025, 00:00

  • EE672 Stop Ignoring Missing Patients the Hidden Impact of Ignoring Missing Data in Health State Utility Estimation

    Dec 1, 2025, 00:00

  • RWD150 Real-World Characterization of Urticaria Subtypes in Brazil: A TriNetX-Based Analysis of Demographics, Comorbidities, Treatments, and Laboratory Markers

    Dec 1, 2025, 00:00

  • EE562 Is Less More? Aggregating Health States in State Transition Models

    Dec 1, 2025, 00:00

  • HPR156 Payer and HTA Evaluation Criteria and Considerations for Coverage and Reimbursement of Patient Self-Monitoring Technology

    Dec 1, 2025, 00:00

  • SA56 Integrating Stakeholder Insights Into Thematic Analysis: Enhancing Efficiency and Supporting HEOR

    Dec 1, 2025, 00:00

  • EE494 Health Economic Modeling Approaches for Assessing the Value of a Clostridioides Difficile Vaccination Program: A Literature Review

    Dec 1, 2025, 00:00

  • EE534 Impact of Inclusion of Drug Adherence on Cost-Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Disease (ASCVD) Patients

    Dec 1, 2025, 00:00

  • PT21 Can Generative AI Deliver Patient-Friendly Summaries? A Case Study Using NICE Guidance for Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • HPR146 Navigating the Influence of Traditional Chinese Medicine (TCM) on the Positioning of New Treatments in China: A Review of TCM Inclusion in Clinical Guidelines

    Dec 1, 2025, 00:00

  • MSR132 Instrumental Variable Treatment Effects Estimation: A Simulation Comparison of Instrumental Variables and OLS Approaches

    Dec 1, 2025, 00:00

  • HPR219 Timing Matters: Missed Opportunity to Prevent RSV Cases in Older Adults in Germany: A Markov Model Analysis

    Dec 1, 2025, 00:00

  • EPH132 Identifying Risk Factors Associated With Meningioma: A Systematic Review

    Dec 1, 2025, 00:00

  • EE422 Estimating Quality-Adjusted Life Expectancy by Ethnicity for Application in Distributional Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • RWD55 Deep Real-World Analysis of Patients With Myelofibrosis Using Natural Language Processing and Machine Learning: A Methods Description

    Dec 1, 2025, 00:00

  • HTA25 Advancing a Greener Ecosystem in Health Technology Assessment: A Review of Environmental Integration as an Additional Value Driver

    Dec 1, 2025, 00:00

  • EE557 Integrating Environmental Sustainability Into Cost-Effectiveness Analysis and Value Demonstration: A Multidimensional Framework

    Dec 1, 2025, 00:00

  • PT29 From Code to Quality: Identifying Quality Assurance Steps for AI Integration in Qualitative Healthcare Research: A Comparative Study of ChatGPT, Atlas.ti, and Traditional Coding

    Dec 1, 2025, 00:00

  • CO59 Comparative Efficacy Safety and Discontinuation of Inhaled Levodopa for Patients With Parkinson’s Disease: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • HSD50 Examination of Muscle Activity Among Aesthetic Sports Athletes

    Dec 1, 2025, 00:00

  • HTA171 Health Equity Considerations in Economic Evaluation: Comparative Acceptability and Application Across European HTA Bodies

    Dec 1, 2025, 00:00

  • MT7 Assessing the Economic Impact of a Robotic-Assisted Solution vs. a Manual Approach in Total Knee Arthroplasty in the UK

    Dec 1, 2025, 00:00

  • EE135 Comparative Analysis of Pan-European Severity Assessment Methods and Their Uncertainty in Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • EPH125 High All-Cause Hospitalization Among Those With Recurrent ASCVD Event: Evidence From a Large-Scale Real-World Database

    Dec 1, 2025, 00:00

  • CO124 Gaps in Cancer Screening Uptake in Ireland: Trends, Barriers and Policy Implications

    Dec 1, 2025, 00:00

  • PCR150 Looking Back to Go Forward: Reintegrating Scientific Considerations Into eCOA Design and Implementation

    Dec 1, 2025, 00:00

  • HSD13 Barriers and Enablers in Health System Redesign

    Dec 1, 2025, 00:00

  • Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Dec 1, 2025, 00:00

  • EE488 Health Economic Analysis of Risk- and Age-Based Pneumococcal Vaccination With PCV21 vs. PCV20 in France

    Dec 1, 2025, 00:00

  • MT46 Value of in Vitro Diagnostic IVD Tests in Health Society and Economy in Portugal

    Dec 1, 2025, 00:00

  • EPH200 Quality of Life of Patients Living With Epilepsy in Hungary

    Dec 1, 2025, 00:00

  • EE641 Reducing External Plasma Dependency: Impact for the Portuguese National Health Service

    Dec 1, 2025, 00:00

  • HTA363 What Generalized Cost-Effectiveness Analysis (GCEA) Reveals About the Applicability of Foreign Reference Pricing in Medicare Price Negotiation in the US

    Dec 1, 2025, 00:00

  • EE169 Cost-Effectiveness of Nemolizumab in the Treatment of Patients With Moderate-to-Severe Prurigo Nodularis in Italy

    Dec 1, 2025, 00:00

  • PCR116 Health-Related Quality of Life in Firstline Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Review With Focus on the PD-L1 Negative Subgroup

    Dec 1, 2025, 00:00

  • CO179 Pharmacist-Led Education Improves Inhaler Satisfaction Adherence and Asthma Control in Asthma Patients

    Dec 1, 2025, 00:00

  • EE568 Long-Term Economic Impact of Nonpersistence to Disease-Modifying Therapies in a Cohort of German Patients With Multiple Sclerosis

    Dec 1, 2025, 00:00

  • HSD6 Analysis of Pharmacists' Awareness on Post COVID-19 Conditions and Implementation in Postgraduate Education in Ukraine

    Dec 1, 2025, 00:00

  • EPH49 Comorbidities of Anxiety Disorders in Children and Adolescents in Germany: A Nationwide Representative Claims Data Analysis

    Dec 1, 2025, 00:00

  • OP8 Frameworks for the Use of AI Within HEOR: A Targeted Literature Review and Thematic Analysis

    Dec 1, 2025, 00:00

  • EE495 Health Utilities Among Patients With Chronic Rhinosinusitis With Nasal Polyps: An Exploratory Analysis From the WAYPOINT Trial

    Dec 1, 2025, 00:00

  • P48 Empirical Comparison of Subjective Well-Being and Health-Related Quality of Life Measures in Australian Adolescents

    Dec 1, 2025, 00:00

  • RWD1 A Description of the Incidence and Burden of Hyperkalemia in Irish Hospitals 2022-2024

    Dec 1, 2025, 00:00

  • MT11 Cost Analysis of the Extravascular Implantable Cardioverter-Defibrillator Compared to the Subcutaneous System in Patients at Risk of Sudden Cardiac Death in Italy

    Dec 1, 2025, 00:00

  • HPR135 Managed Reimbursement of Continuous Glucose Monitoring Sensors in Ireland: Year One Review

    Dec 1, 2025, 00:00

  • HTA314 The Development of the Multicriteria Decision Analysis in Specialized Burn Care: The Methodological Process

    Dec 1, 2025, 00:00

  • SA33 Developmental Rehabilitation in Children With Autism: Utilization and Economic Burden in South Korea

    Dec 1, 2025, 00:00

  • EE88 Budget Impact Analysis of Inclisiran for the Management of Patients With Atherosclerotic Cardiovascular Disease in India: A Multipayer Analysis

    Dec 1, 2025, 00:00

  • CO226 Systematic Literature Review (SLR) of First-Line (1L) Treatments of Patients With Advanced or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma (GEA)

    Dec 1, 2025, 00:00

  • SA107 Zero-Shot RCT Identification Using Large Language Models: A Comparative Study With the Cochrane Classifier

    Dec 1, 2025, 00:00

  • EE370 Economic Evaluation in Alzheimer’s Disease: A Systematic Review

    Dec 1, 2025, 00:00

  • PCR146 Involving Women With Lived Experience of Pelvic Organ Prolapse in Designing and Refining the Economic Components of a Health Technology Assessment

    Dec 1, 2025, 00:00

  • EPH29 Budget Impact of an Organized Cervical Cancer Screening in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • EPH268 Underlying Systemic Motifs That Prevent Diabetes Patients From Seeking and Utilizing Health Services in a Country With a High Prevalence of Diabetes

    Dec 1, 2025, 00:00

  • HSD117 Trends and Economic Impact of Medication Errors in Public Hospitals of Eastern Region Ghana: A Retrospective Analysis From 2018 to 2024

    Dec 1, 2025, 00:00

  • RWD158 Real-World Healthcare Resource Utilization and Related Costs Associated With Bladder Cancer in the Brazilian Private Market

    Dec 1, 2025, 00:00

  • MSR172 Predictive Algorithms in HTA: What Factors Influence Decision Making in NICE, SMC, and NCPE?

    Dec 1, 2025, 00:00

  • EE150 Conceptual Approach to Economic Modeling in Retinal Diseases: A Review and Critique of Two NICE Clinical Guidelines

    Dec 1, 2025, 00:00

  • EE393 Economic Evaluations of Medical Interventions for Adult People Living With Obesity: Protocol for a Systematic Literature Review

    Dec 1, 2025, 00:00

  • RWD21 Assessing the Feasibility of the Implementation of a Subscription Model Pricing Solution Aimed at Broadening Access to All Eligible Patients Within the HER2 Indication

    Dec 1, 2025, 00:00

  • HPR7 A Decade of Change in Turkish Healthcare Utilization: Hospital Admission Trends 2015-2024

    Dec 1, 2025, 00:00

  • HTA210 Integration of Germany’s AMNOG Framework With the Joint Clinical Assessment Process

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6 (current)
  • 7
  • 8
  • 9
  • 10
  • »